Cargando…

Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer

INTRODUCTION: In Asians, more than half of non-small cell lung cancers (NSCLC) are induced by epidermal growth factor receptor (EGFR) mutations. Although patients carrying EGFR driver mutations display a good initial response to EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs), additional mutations provo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qian, Kobayashi, Susumu S., Haeno, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568620/ https://www.ncbi.nlm.nih.gov/pubmed/37841421 http://dx.doi.org/10.3389/fonc.2023.1137966

Ejemplares similares

Mathematical Modeling of Locoregional Recurrence Caused by Premalignant Lesions Formed Before Initial Treatment
por: Takaki, Mitsuaki, et al.
Publicado: (2021)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma
por: Huo, Ji-wen, et al.
Publicado: (2022)

Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
por: Li, Ning, et al.
Publicado: (2022)

Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

A Case of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer: Multi-Line Treatment and Resistance Mechanisms
por: Teixeira, Ana Raquel, et al.
Publicado: (2023)

Computational modeling of locoregional recurrence with spatial structure identifies tissue-specific carcinogenic profiles
por: Abubakar, Sharafudeen Dahiru, et al.
Publicado: (2023)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Cytology–Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non–Small Cell Lung Cancer
por: Chiang, Chi-Lu, et al.
Publicado: (2022)

Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review
por: Song, Chengyang, et al.
Publicado: (2022)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer
por: Hu, Na, et al.
Publicado: (2022)

New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis
por: Zhu, Li-Hua, et al.
Publicado: (2023)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
por: Kelly, William J., et al.
Publicado: (2018)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
por: Peng, Jianfeng, et al.
Publicado: (2021)

High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer
por: Zeng, Tianyu, et al.
Publicado: (2022)

A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and (18)F-FDG Metabolic Activity in Non-Small Cell Lung Cancer
por: Jiang, Maoqing, et al.
Publicado: (2022)

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
por: Zhang, Yuhai, et al.
Publicado: (2022)

The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer
por: Ramanathan, Siddharth, et al.
Publicado: (2023)

The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma
por: Zhao, Wei, et al.
Publicado: (2020)

Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
por: Isobe, Kazutoshi, et al.
Publicado: (2014)

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study
por: Chang, Qing, et al.
Publicado: (2021)

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
por: Ren, Fei, et al.
Publicado: (2022)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer
por: Zhang, Xinyu, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
por: Stein, Shayna, et al.
Publicado: (2018)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
por: Li, Yanping, et al.
Publicado: (2022)

Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma
por: Jiang, Meilin, et al.
Publicado: (2022)

Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer
por: Huang, Xuemei, et al.
Publicado: (2022)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
por: Chen, Fei, et al.
Publicado: (2020)

Correlations Study Between (18)F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma
por: Yang, Bin, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook
por: Miles, Brittany, et al.
Publicado: (2021)

Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Zhang, Xuelin, et al.
Publicado: (2022)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nh1mch1l82rqtfqe51l1k8ahih